National Sickle Cell Awareness Month: What Is Sickle Cell Disease and How Is Research Changing Care?

Every September, communities across the United States observe National Sickle Cell Awareness Month. The month is set aside to educate the public about sickle cell disease, encourage families to learn their genetic status, reduce the stigma that people with the condition still face in daily life and in healthcare settings, and support the research that continues to change what care can look like. The symbol of the observance is a burgundy ribbon, and cities, hospitals, and advocacy groups often light landmarks in red throughout the month.

Sickle cell disease has been recognized in medical literature for more than a century, yet public understanding of the condition remains limited outside the communities most affected by it. National Sickle Cell Awareness Month exists to close that gap. This article explains what the disease is, who it affects, how care has evolved, and why continued clinical research, and diverse participation in it, matters so much.

What is National Sickle Cell Awareness Month, and when is it observed?

National Sickle Cell Awareness Month is observed every September in the United States. Congress formally designated the month in 1983, following a resolution introduced by the Congressional Black Caucus and a presidential proclamation that invited all Americans to renew their commitment to reducing the burden of the disease. The observance was built on earlier community efforts by leading sickle cell advocacy organizations, which had begun holding month-long September events in the mid-1970s.

The month serves several purposes at once. It raises public awareness of a condition that has often been overlooked in mainstream health conversations. It encourages people who may carry a sickle cell gene to learn their status, which supports informed family planning. It also draws attention to the research pipeline, from newer medicines to one-time gene-based therapies, that continues to change what care can look like. Community events, patient stories, and educational campaigns anchor the month, and many families use it as a time to connect with support networks. The DecenTrialz overview on how advocacy groups connect communities to research shows why organized community efforts matter so much for conditions like sickle cell disease.

What is sickle cell disease?

Sickle cell disease is a group of inherited red blood cell disorders. The word "inherited" means the condition is passed from parents to children through genes. The problem lies in hemoglobin, the protein inside red blood cells that carries oxygen from the lungs to the rest of the body. People with sickle cell disease produce an abnormal form of hemoglobin called hemoglobin S. When this abnormal hemoglobin releases its oxygen, it clumps into stiff rods that warp normally round, flexible red blood cells into a rigid crescent or "sickle" shape, named after a curved farm tool.

These sickled cells cause two main problems. They break down early, which leads to chronic anemia, a shortage of healthy red blood cells and, therefore, of oxygen delivery. They also get stuck in small blood vessels, blocking blood flow and starving tissues of oxygen. Those blockages are the root cause of the intense pain episodes and the long-term organ damage that shape life with the disease. Because sickle cell disease affects a smaller share of the general population than more common chronic conditions, it is often grouped with the broader category of rare disease research that DecenTrialz has covered in depth.

It is important to distinguish sickle cell disease from sickle cell trait. Sickle cell disease develops only when a child inherits a sickle cell gene from each parent. When a person inherits one sickle gene and one normal gene, they have sickle cell trait. People with the trait are generally healthy and usually have no symptoms, but they can pass the gene to their children. The most common and typically most severe form of the disease is called sickle cell anemia, in which both inherited genes are the sickle type. Other genotypes, including combinations with hemoglobin C or with beta-thalassemia genes, can produce milder or more severe patterns of illness.

Who does sickle cell disease affect, and what are the symptoms?

Sickle cell disease affects a substantial number of people in the United States, and millions more around the world. The condition is most common in regions where malaria has historically been widespread, because carrying a single sickle cell gene provides some protection against severe malaria. That distribution is reflected in the populations most affected today, including people of African, Hispanic, Caribbean, Middle Eastern, Mediterranean, and South Asian descent. In the United States, the disease disproportionately affects Black and African American communities. Every state now screens newborns for sickle cell disease, which allows care to start early and has meaningfully reduced early childhood deaths from infection.

The symptoms of sickle cell disease vary widely from person to person, but several patterns are common. Pain episodes, sometimes called pain crises or vaso-occlusive crises, happen when sickled cells block small blood vessels. These episodes can affect the arms, legs, back, chest, or abdomen and can last from hours to days. Chronic anemia leads to fatigue and shortness of breath. Acute chest syndrome, a serious lung complication, causes chest pain, fever, and difficulty breathing, and is a leading reason for hospitalization. Children with the most severe form of the disease also face a higher risk of stroke, which is why specialized ultrasound screening of blood flow in the brain is offered in early childhood. Other complications can include repeated infections (because the spleen is often damaged early in life), delayed growth, vision changes, kidney disease, and damage to the joints from blocked blood supply. The DecenTrialz explainer on who qualifies for a clinical trial is a useful next read for families thinking through how a condition like this becomes the subject of organized research.

How is sickle cell disease treated today, and where is research heading?

Care for sickle cell disease has changed significantly over the last three decades. A long-standing disease-modifying medicine works by raising the body’s level of fetal hemoglobin, the type of hemoglobin most people produce before birth, which reduces sickling, pain episodes, and lung complications. Blood transfusions are used to raise the level of healthy red blood cells, particularly in children at high risk of stroke, and iron chelation medicines remove the excess iron that builds up after repeated transfusions. Comprehensive care from a hematology team, along with vaccinations and, for young children, daily preventive antibiotics, helps reduce the risk of serious infections.

For decades, a bone marrow or stem cell transplant from a matched donor was the only established cure, and it remained out of reach for most patients because suitable donors were hard to find. That picture began to change in December 2023, when U.S. regulators approved two one-time gene-based therapies for eligible patients age twelve and older. One approach uses gene editing to switch on the body’s own protective fetal hemoglobin, and the other adds a working gene through a modified virus. Both approaches require collecting a patient’s own blood stem cells, intensive preparation with chemotherapy, and reinfusion of the modified cells. Access remains limited by the small number of authorized centers, the length and intensity of the process, and coverage complexities that federal and state programs are now working to address.

Pain management, quality-of-life support, and the transition from pediatric to adult care are also active areas of clinical research and policy attention. The broader legal and regulatory framework that supports research into uncommon conditions has been shaped over many decades, and the law that shaped rare disease research offers useful context on how policy has historically driven progress for smaller patient populations.

Why does diverse participation in sickle cell research matter, and how can families learn about it?

Clinical research is only as strong as the data it produces, and that data is only as representative as the people who take part. Historically, Black and African American communities, along with other groups most affected by sickle cell disease, have been underrepresented in clinical research. That gap exists because the healthcare system has not always made participation accessible, and because a long history of unethical research, including the U.S. Public Health Service Syphilis Study at Tuskegee, left an understandable legacy of mistrust. Present-day barriers, including distance from specialized centers, out-of-pocket costs, missed work, and a lack of clear information about active studies, continue to make participation harder for the very communities the research is meant to serve. The framing here matters. The problem is a system that has not built enough on-ramps, not a community unwilling to take part. A closer look at why diverse participation matters draws out this point in the context of related awareness efforts.

Awareness month is a fitting time for families to learn what research options may exist and how to ask questions with confidence. Comprehensive sickle cell centers, hematology teams, and advocacy organizations can point people toward studies that may be a fit, and toward the education and support that can help them decide. DecenTrialz is a clinical trial recruitment platform that uses AI-assisted participant matching and registered nurse-led pre-screening to help people find studies that could be relevant to their situation. Final eligibility determination, study walk-through, informed consent, and enrollment always belong to the research site team. Anyone considering participation in a study should also talk with their own care team, and organizations that support the sickle cell community can be a valuable starting point.

Frequently asked questions about National Sickle Cell Awareness Month

What color is the sickle cell awareness ribbon?

The awareness ribbon for sickle cell disease is burgundy, sometimes described as dark red. Buildings and landmarks are often lit in red during September.

When is National Sickle Cell Awareness Month?

It is observed every September in the United States. World Sickle Cell Day, a separate global observance recognized by the United Nations, falls on June 19.

Is there a cure for sickle cell disease?

A bone marrow or stem cell transplant from a matched donor has long been the only established cure. In December 2023, U.S. regulators approved two one-time gene-based therapies for eligible patients age twelve and older, though access remains limited by the small number of authorized centers and the intensity of the process.

What is the difference between sickle cell disease and sickle cell trait?

Sickle cell disease develops when a child inherits a sickle cell gene from each parent. Sickle cell trait means inheriting one sickle gene and one normal gene. People with the trait are generally healthy and usually have no symptoms, but they can pass the gene to their children.

A month for awareness, and a call for continued research

National Sickle Cell Awareness Month is more than a symbolic observance. It is a yearly opportunity to bring accurate information forward, to close persistent gaps in care and understanding, and to invite broader participation in the research that continues to change outcomes. Awareness on its own does not deliver medicine, but it lays the foundation that makes better care and better research possible.